IHL News: Independent data review commences for Phase 2 trial of psilocybin-assisted psychotherapy for anxiety - 19th Jan 2023, 12:00am

annb0t

Top 20
Incannex Healthcare

MELBOURNE, Australia, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that the PsiGAD1 clinical trial, designed to assess Incannex’s psilocybin-assisted psychotherapy for the treatment of generalised anxiety disorder (â...

>>> Read more: Independent data review commences for Phase 2 trial of psilocybin-assisted psychotherapy for anxiety
 
Top Bottom